Hydronephrosis Market Overview
Hydronephrosis Market Size was valued at USD 3.22 Billion in 2023. The Global Hydronephrosis industry is projected to grow from USD 3.57 Billion in 2024 to USD 8.16 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.20% during the forecast period (2024 - 2032).
Hydronephrosis is a condition characterized by a swollen kidney as a result of abnormal drainage of urine from the kidney to the bladder. It is a secondary disease that results from primary disease that may affect the kidney. Symptoms of hydronephrosis includes fever, pain when urinating, nausea or vomiting, and pain in the abdomen. It may be unilateral or bilateral. Unilateral hydronephrosis is swelling of one kidney, whereas, bilateral hydronephrosis is swelling of both the kidneys. Hydronephrosis is mostly diagnosed through ultrasound examination.
Hydronephrosis has become a major problem across the globe due to rising prevalence of kidney diseases, lack of awareness about the diseases and their treatment, which favor the growth of the market. Rising prevalence of kidney diseases especially, in the geriatric population and availability of cost-effective treatment propel the market growth.
Hydronephrosis Market Segment Insights
The hydronephrosis market is segmented on the basis of types, which includes unilateral hydronephrosis and bilateral hydronephrosis.
Hydronephrosis Diagnosis Insights
On the basis of diagnosis, the hydronephrosis market is segmented into laboratory test and imaging. Laboratory test is further segmented into urinalysis, Complete Blood Count (CBC), electrolyte analysis, and others. Imaging is further sub-segmented into CT scan, ultrasound, intravenous pyelography, KUB X-rays, and others.
Hydronephrosis Treatment Insights
On the basis of treatment, the hydronephrosis market is segmented into shock wave lithotripsy, laparoscopy, bladder catheterization, steroid therapy, and others.
Hydronephrosis Indication Insights
On the basis of indication the hydronephrosis market is segmented into intrinsic and extrinsic causes of hydronephrosis. The intrinsic causes are further sub-segmented into acute unilateral obstructive uropathy, kidney stone, bladder cancer, bladder stones, cystocele, urethral stricture, urethral cancer and others. The extrinsic causes are further sub-segmented into retroperitoneal fibrosis, ovarian vein syndrome, cancer of the cervix, cancer of the prostate, uterine prolapse, prostate cancer, and others.
Hydronephrosis Regional Insights
The American region accounted for the largest share of the global market due to increasing prevalence of chronic kidney diseases, and rising demand for diagnosis and treatment of hydronephrosis. Hydronephrosis are leading urological diseases in the U.S. According to the Center for Diseases Control and Prevention, 48,146 deaths occurred due to nephrosis and kidney diseases in the year 2014. It also stated that the number of adults diagnosed with kidney diseases in 2014 was 4.9 million in the US.
Europe is the second largest market that holds a noticeable share of the hydronephrosis market. According to the European database for surveillance of congenital malformations report, hydronephrosis is prevalence among new born and pregnant women.
In Asia Pacific, rising prevalence of kidney stone, rising geriatric population and growing demand for counselling about hydronephrosis drive the market growth.
The Middle East & Africa is expected to show a steady growth in this market due constant demand for diagnostics devices, awareness about maternal and child health in most of the African countries and the government efforts to cater primary health need of the population.The report on the hydronephrosis market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The hydronephrosis market report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.
Key Players in the Hydronephrosis Market
Some of the key players in hydronephrosis market are
- NephroGenex, Inc. (U.S)
- American Renal Associates (U.S)
- PHRAXIS, INC. (U.S)
- Renal Associates P.A. (U.S)
- ALLERGAN (U.S)
- Amgen Inc. (U.S)
- Anthem Bio Pharm (U.S)
- Sanofi (U.S)
- Novartis AG (Germany)
Intended Audience
- Medical Device Manufacturers
- Medical Device Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Report Attribute/Metric
|
Details
|
Market Size
|
2032: USD 8.16 Billion
|
CAGR
|
11.20% (2024-2032)
|
Base Year
|
2023
|
Forecast Period
|
2024-2032
|
Historical Data
|
2022
|
Forecast Units
|
Value (USD Billion)
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
Segments Covered
|
Type, Diagnosis, Treatment, Indication
|
Geographies Covered
|
North America, Europe, Asia-Pacific, and Rest of the World (RoW)
|
Key Vendors
|
NephroGenex, Inc. (U.S), American Renal Associates (U.S), PHRAXIS, INC. (U.S), Renal Associates P.A. (U.S), ALLERGAN (U.S), Amgen Inc. (U.S), Anthem Bio Pharm (U.S), Sanofi (U.S), and Novartis AG (Germany)
|
Key Market Opportunities
|
New product launches and R&D Amongst major key Players
|
Key Market Drivers
|
· Rising prevalence of kidney diseases
· Lack of awareness about the diseases and their treatment
|
Hydronephrosis Market Highlights:
Frequently Asked Questions (FAQ) :
Hydronephrosis market is projected to grow at a 11.20% CAGR between 2024- 2032.
The Americas is expected to dominate the hydronephrosis market.
Hydronephrosis market is predicted to touch USD 8.16 Billion by 2032.
Rising prevalence of kidney disease and availability of cost-effective treatment are the key factors driving the hydronephrosis market.
Notable players profiled in the hydronephrosis market include Novartis AG (Germany), Sanofi (U.S), Anthem Bio Pharm (U.S), Amgen Inc. (U.S), ALLERGAN (U.S), Renal Associates P.A. (U.S), PHRAXIS, INC. (U.S), American Renal Associates (U.S), and NephroGenex, Inc. (U.S).